| Anna Stidham, MD | |
|
1200 Everett Dr, 1 Np 606, Oklahoma City, OK 73104-5047 | |
| (405) 271-5125 | |
| Not Available |
| Full Name | Anna Stidham |
|---|---|
| Gender | Female |
| Speciality | Diagnostic Radiology |
| Experience | 21 Years |
| Location | 1200 Everett Dr, Oklahoma City, Oklahoma |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114066180 | NPI | - | NPPES |
| 200134480A | Medicaid | OK |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 23436 (Oklahoma) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ssm Health St Anthony Hospital - Oklahoma City | Oklahoma city, OK | Hospital |
| Ssm Health St Anthony Hospital - Shawnee | Shawnee, OK | Hospital |
| Oklahoma Heart Hospital South, Llc | Oklahoma city, OK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Oklahoma Radiology Group P C | 9032101688 | 15 |
| Premier Breast Health Institute Of Oklahoma Llc | 6406202753 | 2 |
News Archive
Banook Group, an international provider of cardiac safety, central imaging and endpoint adjudication services, today announces that its three subsidiaries will now be combined into one unique name and brand.
AstraZeneca (NYSE: AZN) today announced that data from a Phase III study of postmenopausal women with hormone receptor-positive advanced breast cancer presented at the San Antonio Breast Cancer Symposium (Abstract 25) showed treatment with fulvestrant (FASLODEX) 500 mg reduced the risk of disease progression (assessed as time to progression (TTP)) by 20%
Bristol-Myers Squibb Company (NYSE: BMY) announced today that the Hart-Scott-Rodino (HSR) review period for its tender offer for Medarex, Inc. (NASDAQ: MEDX) has expired.
While the proven negative health consequences of smoking and tanning are undeniable, tobacco and indoor tanning advertisers would like consumers to think otherwise. In fact, a new study comparing the tactics used in advertising tobacco and indoor tanning products found several similarities in how these two industries market unhealthy products.
› Verified 8 days ago
| Entity Name | Ctca Physicans Group Of Oklahoma, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053309591 PECOS PAC ID: 2163328774 Enrollment ID: O20031212000074 |
News Archive
Banook Group, an international provider of cardiac safety, central imaging and endpoint adjudication services, today announces that its three subsidiaries will now be combined into one unique name and brand.
AstraZeneca (NYSE: AZN) today announced that data from a Phase III study of postmenopausal women with hormone receptor-positive advanced breast cancer presented at the San Antonio Breast Cancer Symposium (Abstract 25) showed treatment with fulvestrant (FASLODEX) 500 mg reduced the risk of disease progression (assessed as time to progression (TTP)) by 20%
Bristol-Myers Squibb Company (NYSE: BMY) announced today that the Hart-Scott-Rodino (HSR) review period for its tender offer for Medarex, Inc. (NASDAQ: MEDX) has expired.
While the proven negative health consequences of smoking and tanning are undeniable, tobacco and indoor tanning advertisers would like consumers to think otherwise. In fact, a new study comparing the tactics used in advertising tobacco and indoor tanning products found several similarities in how these two industries market unhealthy products.
› Verified 8 days ago
| Entity Name | Oklahoma Radiology Group P C |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841283165 PECOS PAC ID: 9032101688 Enrollment ID: O20040401001538 |
News Archive
Banook Group, an international provider of cardiac safety, central imaging and endpoint adjudication services, today announces that its three subsidiaries will now be combined into one unique name and brand.
AstraZeneca (NYSE: AZN) today announced that data from a Phase III study of postmenopausal women with hormone receptor-positive advanced breast cancer presented at the San Antonio Breast Cancer Symposium (Abstract 25) showed treatment with fulvestrant (FASLODEX) 500 mg reduced the risk of disease progression (assessed as time to progression (TTP)) by 20%
Bristol-Myers Squibb Company (NYSE: BMY) announced today that the Hart-Scott-Rodino (HSR) review period for its tender offer for Medarex, Inc. (NASDAQ: MEDX) has expired.
While the proven negative health consequences of smoking and tanning are undeniable, tobacco and indoor tanning advertisers would like consumers to think otherwise. In fact, a new study comparing the tactics used in advertising tobacco and indoor tanning products found several similarities in how these two industries market unhealthy products.
› Verified 8 days ago
| Entity Name | Creek Nation Hospital & Clinics |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366593923 PECOS PAC ID: 5698786226 Enrollment ID: O20070821000130 |
News Archive
Banook Group, an international provider of cardiac safety, central imaging and endpoint adjudication services, today announces that its three subsidiaries will now be combined into one unique name and brand.
AstraZeneca (NYSE: AZN) today announced that data from a Phase III study of postmenopausal women with hormone receptor-positive advanced breast cancer presented at the San Antonio Breast Cancer Symposium (Abstract 25) showed treatment with fulvestrant (FASLODEX) 500 mg reduced the risk of disease progression (assessed as time to progression (TTP)) by 20%
Bristol-Myers Squibb Company (NYSE: BMY) announced today that the Hart-Scott-Rodino (HSR) review period for its tender offer for Medarex, Inc. (NASDAQ: MEDX) has expired.
While the proven negative health consequences of smoking and tanning are undeniable, tobacco and indoor tanning advertisers would like consumers to think otherwise. In fact, a new study comparing the tactics used in advertising tobacco and indoor tanning products found several similarities in how these two industries market unhealthy products.
› Verified 8 days ago
| Entity Name | Premier Breast Health Institute Of Oklahoma Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538860234 PECOS PAC ID: 6406202753 Enrollment ID: O20231024000860 |
News Archive
Banook Group, an international provider of cardiac safety, central imaging and endpoint adjudication services, today announces that its three subsidiaries will now be combined into one unique name and brand.
AstraZeneca (NYSE: AZN) today announced that data from a Phase III study of postmenopausal women with hormone receptor-positive advanced breast cancer presented at the San Antonio Breast Cancer Symposium (Abstract 25) showed treatment with fulvestrant (FASLODEX) 500 mg reduced the risk of disease progression (assessed as time to progression (TTP)) by 20%
Bristol-Myers Squibb Company (NYSE: BMY) announced today that the Hart-Scott-Rodino (HSR) review period for its tender offer for Medarex, Inc. (NASDAQ: MEDX) has expired.
While the proven negative health consequences of smoking and tanning are undeniable, tobacco and indoor tanning advertisers would like consumers to think otherwise. In fact, a new study comparing the tactics used in advertising tobacco and indoor tanning products found several similarities in how these two industries market unhealthy products.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Anna Stidham, MD 940 Stanton L Young Blvd, Bmsb 357, Oklahoma City, OK 73104-5020 Ph: () - | Anna Stidham, MD 1200 Everett Dr, 1 Np 606, Oklahoma City, OK 73104-5047 Ph: (405) 271-5125 |
News Archive
Banook Group, an international provider of cardiac safety, central imaging and endpoint adjudication services, today announces that its three subsidiaries will now be combined into one unique name and brand.
AstraZeneca (NYSE: AZN) today announced that data from a Phase III study of postmenopausal women with hormone receptor-positive advanced breast cancer presented at the San Antonio Breast Cancer Symposium (Abstract 25) showed treatment with fulvestrant (FASLODEX) 500 mg reduced the risk of disease progression (assessed as time to progression (TTP)) by 20%
Bristol-Myers Squibb Company (NYSE: BMY) announced today that the Hart-Scott-Rodino (HSR) review period for its tender offer for Medarex, Inc. (NASDAQ: MEDX) has expired.
While the proven negative health consequences of smoking and tanning are undeniable, tobacco and indoor tanning advertisers would like consumers to think otherwise. In fact, a new study comparing the tactics used in advertising tobacco and indoor tanning products found several similarities in how these two industries market unhealthy products.
› Verified 8 days ago
Dr. Jennifer Kathleen Hinkle, MD Radiology Medicare: Medicare Enrolled Practice Location: 921 Ne 13th St, Oklahoma City, OK 73104 Phone: 405-456-2589 | |
Dr. Bryan Lee Vanzandt, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 4625 S Western Ave, Oklahoma City, OK 73109 Phone: 405-632-2323 Fax: 405-631-9315 | |
Charles Eric Eckman, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 14101 Parkway Commons, Oklahoma City, OK 73134 Phone: 405-749-6277 | |
Robert K Gelczer, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 3433 Nw 56th St., Suite C-40, Oklahoma City, OK 73112 Phone: 405-945-4741 Fax: 888-972-5320 | |
Vikas Vij, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 3433 Nw 56th St, Suite C-40, Oklahoma City, OK 73112 Phone: 405-945-4741 Fax: 888-972-5320 | |
William G Phillips, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 2224 Nw 50th St, Suite 276w, Oklahoma City, OK 73112 Phone: 405-858-2350 | |
Ronald Ray Magee, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 5224 E I 240 Service Rd Ste 303, Oklahoma City, OK 73135 Phone: 405-608-3800 Fax: 405-628-6477 |